Skip to main navigation

Careers
Investors & Media
Contact

SCIENCE
PIPELINE
DISEASE FOCUS
HAE COMMUNITY
CLINICAL TRIALS
ABOUT US

Events

Investor Menu

IR Nav

Overview
News & Events
News Releases Events Publications
Financials
SEC Filings Quarterly Results
Stock
Stock Performance Analyst Coverage
Corporate Governance
Governance Documents Leadership Board of Directors Committee Composition
Resources
Investor FAQs Contact Us Email Alerts

Past Events

May 10, 2023 4:35 PM PDT

BofA Securities 2023 Healthcare Conference

Click for Webcast

May 4 - May 7, 2023

13th C1-inhibitor Deficiency and Angioedema Workshop

Supporting Materials

Deucrictibant Data Highlighted in Multiple Presentations at the C1-Inhibitor Deficiency and Angioedema Workshop

The EC85 Derived from the Oral Bradykinin B2 Receptor Antagonist Deucrictibant (PHA121) Against Bradykinin Effects in Healthy Volunteers Predicts the Onset and Duration of Its Clinical Effects in Hereditary Angioedema 1.1 MB

Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate Release Capsule (PHVS416) in Treatment of Hereditary Angioedema Attacks: Topline Results of RAPIDe 1 Phase 2 Trial 870.7 KB

Early symptom relief following treatment with the oral bradykinin 2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in patients with hereditary angioedema attacks 850.4 KB

Cardiovascular safety of the orally administered bradykinin B2 receptor antagonist, deucrictibant (PHA121, PHA-022121) 1.1 MB

Efficacy of the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) by attack location in the RAPIDe-1 phase 2 clinical trial for treatment of hereditary angioedema attacks 1.6 MB

Mar 18, 2023 11:35 AM +07

2023 HAEi Regional Conference APAC

Supporting Materials

Efficacy and Safety of Bradykinin B2 Receptor Inhibition with Oral PHVS416 in Treating Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial 920.2 KB

Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks Highlighted at the 2023 HAEi Regional Conference APAC

Mar 13, 2023 8:00 AM EDT

Oppenheimer 33rd Annual Healthcare Conference

Click for Webcast

Mar 9, 2023

BioCapital Europe 2023

Feb 26, 2023 9:45 AM CST

AAAAI Annual Meeting 2023

Supporting Materials

Efficacy and Safety of Bradykinin B2 Receptor Inhibition with Oral PHVS416 in Treating Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial 1.1 MB

Dr. Marcus Maurer Audio Session (MP4) 6.3 MB

Pharvaris to Highlight Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks at AAAAI Annual Meeting

Feb 15, 2023 8:40 AM EST

SVB Securities Global Biopharma Conference

Click for Webcast

Dec 8, 2022 8:00 AM EST

RAPIDe-1 Phase 2 Top-line Data

Click for Webcast

Supporting Materials

Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks 193.1 KB

RAPIDe-1 Phase 2 Top-line Data Presentation 2.2 MB

Nov 10 - Nov 14, 2022

ACAAI Annual Scientific Meeting 2022

Supporting Materials

Pharvaris to Present PHVS416 and PHVS719 Clinical Data for Treatment of HAE at the ACAAI Annual Scientific Meeting 2022

Development of PHVS719: an Oral Extended-Release Bradykinin B2 Receptor Antagonist to Prevent Hereditary Angioedema Attacks 818.4 KB

Pharmacokinetics of PHVS719, extended-release tablet formulation of PHA121, a first-in-class oral human bradykinin B2-receptor antagonist 937.4 KB

Oct 7, 2022 2:30 PM CEST

2022 HAEi Global Leadership Workshop

Supporting Materials

Development of two novel oral formulations of a first in class bradykinin B2 receptor antagonist for on demand and prophylactic treatment of hereditary angioedema 920.1 KB

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
Next page
Last page

Presentations

Corporate Presentation

FOLLOW US

©2023 Pharvaris N.V. © All Rights Reserved

Privacy Policy
Terms of Use